Sign Up
Stories
AEON Biopharma Advances Migraine Treatment
Share
ACTICOR BIOTECH Delays Key Documents
Advancements in Cancer Treatment and Mar...
Altamira Therapeutics' Peptide-Based Del...
4P-Pharma Secures €15 Million Funding
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
Overview
API
AEON Biopharma progresses its ABP-450 migraine programs, secures FDA Phase 3 alignment, and announces $15 million private placement for further development. The company specializes in a botulinum toxin complex aimed at treating medical conditions.
Ask a question
How might the success of AEON Biopharma's ABP-450 programs impact the treatment landscape for migraines?
In what ways could the private placement of $15 million influence AEON Biopharma's research and development efforts?
What competitive advantages does AEON Biopharma gain from securing FDA alignment for Phase 3 trials?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage